Navigation Links
BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call
Date:11/11/2008

PLYMOUTH MEETING, Pa., Nov. 11 /Xinhua-PRNewswire-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) ("BMP Sunstone" or the "Company"), today announced that due to the technical difficulties encountered on today's conference call, the company will hold a second call tomorrow, Wednesday, November 12, 2008. On this call, BMP Sunstone will give callers the opportunity to ask questions since technical difficulties prevented the Company from addressing all questions on today's call. The transcript of today's call will be posted on the company's website as soon as possible.

Details for Wednesday's Call

The Company will hold a conference call at 9:00 am ET on Wednesday, November 12, 2008. Listeners may access the call by dialing 1-888-713-4214 or 1-617.213.4866 for international callers, access code 93845949. A webcast will also be available through the Company's website at http://www.bmpsunstone.com . A replay of the call will be available through November 19, 2008. Listeners may access the replay by dialing 1-888-286-8010 or 1 617-801-6888 for international callers, access code: 41091128.

About BMP Sunstone Corporation

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China. Currently this portfolio includes eight products under exclusive multi-year licenses for China, primarily focused on women's health and pediatrics. The Company also owns Sunstone Pharmaceutical Co. Ltd., which manufactures leading pediatric and women's health products, including two of China's most recognized brands, "Hao Wawa" and "Confort," sold through approximately 50,000 pharmacies in China. The Company also provides pharmaceutical distribution services through its subsidiaries in Beijing and Shanghai, and through its affiliate, Guangzhou Pharmaceuticals Corp. The Company has its main office in Beijing, with a US office in Plymouth Meeting, PA. For more information, please visit http://www.bmpsunstone.com .

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts, including but not limited to statements about the timing of the completion and terms of the proposed acquisition of 75% of Shengda, the Company's revenue and net income guidance for 2008, the timing of the launch of GoodBaby Multivitamin Granules or any other Company products, use of proceeds from the registered direct offering, the possibility of completing any future acquisitions or receiving profits from Alliance BMP Limited, the ability to successfully integrate the Company's distribution platform, the ability to realize synergies among existing and new Rx and OTC products and channels, future investment in the Company's product portfolio and national leading brands, the focus of the Company on revenue growth and market penetration of the Company's current products, expansion of the Company's product portfolio at BMP China, and solidification of Sunstone's market leader position. These statements are subject to uncertainties and risks including, but not limited to, negotiating definitive terms and definitive agreements regarding the proposed acquisition, satisfying the conditions in such definitive agreements, regulatory review, sales and marketing, operating performance, general financial, economic, and political conditions affecting the biotechnology and pharmaceutical industries and the Chinese pharmaceutical market, the ability to timely manufacture and distribute the Company's products, the need to use cash for unexpected reasons, the results of Alliance BMP Limited operations are less than expected or Alliance BMP Limited decides not to make a distribution of profits to its equityholders, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BMP Sunstone Reports Third Quarter 2008 Financial Results
2. BMP Sunstone Announces Participation in November Investor Conferences
3. BMP Sunstone Announces Participation in September Investor Conference
4. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
5. BMP Sunstone Reports Second Quarter 2008 Financial Results
6. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
7. BMP Sunstone Receives Import Drug License (IDL) from SFDA
8. BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial
9. Follow-up Phone Surveys: Effective Customer Service Assessment Tool for Improving Satisfaction
10. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
11. Kendle to Present at the 2008 Credit Suisse Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of ... offering. ... The Global Market for Bioproducts Should Reach $714.6 Billion ... of 8.9%, This research report quantifies the ... product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
Breaking Biology Technology:
(Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
Breaking Biology News(10 mins):